|Genome sequencing identifies a basis for everolimus sensitivity|
G Iyer, AJ Hanrahan, MI Milowsky, H Al-Ahmadie, SN Scott, ...
Science 338 (6104), 221-221, 2012
|Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology|
JS Damrauer, KA Hoadley, DD Chism, C Fan, CJ Tiganelli, SE Wobker, ...
Proceedings of the National Academy of Sciences 111 (8), 3110-3115, 2014
|Convergent loss of PTEN leads to clinical resistance to a PI (3) Kα inhibitor|
D Juric, P Castel, M Griffith, OL Griffith, HH Won, H Ellis, SH Ebbesen, ...
Nature 518 (7538), 240-244, 2015
|Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma|
EM Van Allen, KW Mouw, P Kim, G Iyer, N Wagle, H Al-Ahmadie, C Zhu, ...
Cancer discovery 4 (10), 1140-1153, 2014
|Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer|
G Iyer, H Al-Ahmadie, N Schultz, AJ Hanrahan, I Ostrovnaya, AV Balar, ...
Journal of Clinical Oncology 31 (25), 3133, 2013
|Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: an exploratory multi-omic analysis|
A Snyder, T Nathanson, SA Funt, A Ahuja, J Buros Novik, MD Hellmann, ...
PLoS medicine 14 (5), e1002309, 2017
|BRAF mutation is associated with early stage disease and improved outcome in patients with low‐grade serous ovarian cancer|
RN Grisham, G Iyer, K Garg, D DeLair, DM Hyman, Q Zhou, A Iasonos, ...
Cancer 119 (3), 548-554, 2013
|Phase II study of everolimus in metastatic urothelial cancer|
MI Milowsky, G Iyer, AM Regazzi, H Al-Ahmadie, SR Gerst, I Ostrovnaya, ...
BJU international 112 (4), 462, 2013
|Genomic characterization of upper tract urothelial carcinoma|
JP Sfakianos, EK Cha, G Iyer, SN Scott, EC Zabor, RH Shah, Q Ren, ...
European urology 68 (6), 970-977, 2015
|DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma|
MY Teo, RM Bambury, EC Zabor, E Jordan, H Al-Ahmadie, ME Boyd, ...
Clinical cancer research 23 (14), 3610-3618, 2017
|Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder|
PH Kim, EK Cha, JP Sfakianos, G Iyer, EC Zabor, SN Scott, I Ostrovnaya, ...
European urology 67 (2), 198-201, 2015
|Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy|
H Al-Ahmadie, G Iyer, M Hohl, S Asthana, A Inagaki, N Schultz, ...
Cancer discovery 4 (9), 1014-1021, 2014
|Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer|
HA Al-Ahmadie, G Iyer, BH Lee, SN Scott, R Mehra, A Bagrodia, ...
Nature genetics 48 (4), 356-358, 2016
|Genetic determinants of cisplatin resistance in patients with advanced germ cell tumors|
A Bagrodia, BH Lee, W Lee, EK Cha, JP Sfakianos, G Iyer, EJ Pietzak, ...
Journal of Clinical Oncology 34 (33), 4000, 2016
|Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells|
G Redelman-Sidi, G Iyer, DB Solit, MS Glickman
Cancer research 73 (3), 1156-1167, 2013
|Extreme outlier analysis identifies occult mitogen-activated protein kinase pathway mutations in patients with low-grade serous ovarian cancer|
RN Grisham, BE Sylvester, H Won, G McDermott, D DeLair, R Ramirez, ...
Journal of Clinical Oncology 33 (34), 4099, 2015
|Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors|
DR Feldman, G Iyer, L Van Alstine, S Patil, H Al-Ahmadie, VE Reuter, ...
Clinical Cancer Research 20 (14), 3712-3720, 2014
|Somatic mutation of fibroblast growth factor receptor‐3 (FGFR3) defines a distinct morphological subtype of high‐grade urothelial carcinoma|
HA Al‐Ahmadie, G Iyer, M Janakiraman, O Lin, A Heguy, SK Tickoo, ...
The Journal of pathology 224 (2), 270-279, 2011
|Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer|
RN Grisham, G Iyer, E Sala, Q Zhou, A Iasonos, D DeLair, DM Hyman, ...
International Journal of Gynecologic Cancer 24 (6), 2014
|Fibroblast growth factor receptor-3 in urothelial tumorigenesis|
G Iyer, MI Milowsky
Urologic Oncology: Seminars and Original Investigations 31 (3), 303-311, 2013